source
- Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese dataErasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…
- Study finds stopping statins in older adults may lead to worse outcomes despite non-inferior labelA new trial called STREAM examined whether older adults without prior heart attacks or strokes could safely stop taking statins. The study was presented at the American Heart Association annual mee…